Lipidomics in non-alcoholic fatty liver disease

被引:0
|
作者
Sofia Kartsoli [1 ]
Christina E Kostara [2 ]
Vasilis Tsimihodimos [3 ]
Eleni T Bairaktari [2 ]
Dimitrios K Christodoulou [1 ]
机构
[1] Department of Gastroenterology, School of Health Sciences, Faculty of Medicine, University of Ioannina
[2] Laboratory of Clinical Chemistry, School of Health Sciences, Faculty of Medicine, University of Ioannina
[3] Department of Internal Medicine, School of Health Sciences, Faculty of Medicine, University of Ioannina
关键词
D O I
暂无
中图分类号
R575.5 [肝代谢障碍];
学科分类号
1002 ; 100201 ;
摘要
Non-alcoholic fatty liver disease(NAFLD), the most common chronic liver disorder in Western countries, comprises steatosis to nonalcoholic steatohepatitis(NASH), with the latter having the potential to progress to cirrhosis. The transition from isolated steatosis to NASH is still poorly understood, but lipidomics approach revealed that the hepatic lipidome is extensively altered in the setting of steatosis and steatohepatitis and these alterations correlate with disease progression. Recent data suggest that both quantity and quality of the accumulated lipids are involved in pathogenesis of NAFLD. Changes in glycerophospholipid, sphingolipid, and fatty acid composition have been described in both liver biopsies and plasma of patients with NAFLD, implicating that specific lipid species are involved in oxidative stress, inflammation, and cell death. In this article, we summarize the findings of main human lipidomics studies in NAFLD and delineate the currently available information on the pathogenetic role of each lipid class in lipotoxicity and disease progression.
引用
收藏
页码:436 / 450
页数:15
相关论文
共 50 条
  • [1] Lipidomics in non-alcoholic fatty liver disease
    Kartsoli, Sofia
    Kostara, Christina E.
    Tsimihodimos, Vasilis
    Bairaktari, Eleni T.
    Christodoulou, Dimitrios K.
    WORLD JOURNAL OF HEPATOLOGY, 2020, 12 (08) : 436 - 450
  • [2] Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
    Huang, Jian
    Sigon, Giordano
    Mullish, Benjamin H.
    Wang, Dan
    Sharma, Rohini
    Manousou, Pinelopi
    Forlano, Roberta
    NUTRIENTS, 2023, 15 (08)
  • [3] Cancer surveillance in non-alcoholic fatty liver disease: A potential role for lipidomics
    Best, Jan
    Bechmann, Lars P.
    EBIOMEDICINE, 2021, 74
  • [4] Lipoprotein Lipidomics as a Frontier in Non-Alcoholic Fatty Liver Disease Biomarker Discovery
    Herrera-Marcos, Luis V.
    Arbones-Mainar, Jose M.
    Osada, Jesus
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (15)
  • [5] Advances in pediatric non-alcoholic fatty liver disease:From genetics to lipidomics
    Simona Riccio
    Rosa Melone
    Caterina Vitulano
    Pierfrancesco Guida
    Ivan Maddaluno
    Stefano Guarino
    Pierluigi Marzuillo
    Emanuele Miraglia del Giudice
    Anna Di Sessa
    World Journal of Clinical Pediatrics, 2022, 11 (03) : 221 - 238
  • [6] Non-alcoholic Fatty Liver Disease
    Tan, Hui-Hui
    Chang, Jason Pik-Eu
    PROCEEDINGS OF SINGAPORE HEALTHCARE, 2010, 19 (01) : 36 - 50
  • [7] Non-alcoholic fatty liver disease
    Angulo, P
    Lindor, KD
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 : S186 - S190
  • [8] Non-alcoholic fatty liver disease
    Powell, Elizabeth E.
    Wong, Vincent Wai-Sun
    Rinella, Mary
    LANCET, 2021, 397 (10290): : 2212 - 2224
  • [9] Non-alcoholic fatty liver disease
    Maurice, James
    Manousou, Pinelopi
    CLINICAL MEDICINE, 2018, 18 (03) : 245 - 250
  • [10] Non-alcoholic fatty liver disease
    Neuschwander-Tetri, Brent A.
    BMC MEDICINE, 2017, 15